Literature DB >> 12856175

Congenital toxoplasmosis: assessment of risk to newborns in confirmed and uncertain maternal infection.

Mariangela Mombrò1, Cristina Perathoner, Agata Leone, Vittorina Buttafuoco, Carla Zotti, Maria Alessandra Lievre, Claudio Fabris.   

Abstract

UNLABELLED: We identified 205 newborns at risk of congenital infection based on their mothers' immunological status during pregnancy, using the criteria established by the European Research Network on Congenital Toxoplasmosis to define the likelihood of infection in pregnant women. Of the 205 newborns, 60 (29.2%) were born to mothers with documented seroconversion, 49 (23.9%) to mothers with probable infection, 60 (29.2%) to mothers with possible infection, and 36 (17.6%) to mothers who were unlikely to be infected. Infection was transmitted to the child in 13 out of 60 cases (21.6%) of seroconversion, in 2 out of 49 (4.1%) cases of probable infections and in none of the possible and unlikely cases. The results were further analysed considering only the 109 newborns of mothers with confirmed and probable infection; in this group, toxoplasmosis was not transmitted to any of the 45 newborns of mothers infected in the first trimester of pregnancy, whereas it was transmitted to 5 out of 29 (17.2%) cases of seroconversion and 2 out of 12 (16.6%) with probable infection in the second trimester, and to 8 out of 23 (34.8%) with confirmed infection in the third trimester (no probable infections were dated in the third trimester). Among the newborns of mothers with seroconversion, the risk of symptomatic infection was 10.4% in the second trimester and 8.7% in the third trimester.
CONCLUSION: the authors have quantified the risk of transmission of toxoplasmosis infection, not only in cases of seroconversion, as reported by others, but also in infections defined as probable or possible based on presence of IgM and/or IgA and with medium-high IgG levels. Probable infections in the second trimester of pregnancy carries the same risk of transmission as seroconversions and pregnant women and their newborns in these cases should undergo the same diagnostic and therapeutic approach. It is suggested that newborns of mothers with certain and probable infection must be carefully observed and undergo clinical and serological testing to identify and treat the infection as soon as possible. In the case of possible or unlikely maternal infection, serological testing at longer intervals is nevertheless advisable without the need for treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12856175     DOI: 10.1007/s00431-003-1248-1

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  9 in total

1.  Diagnosis of congenital toxoplasmosis at birth: what is the value of testing for IgM and IgA?

Authors:  M Wallon; D Dunn; D Slimani; V Girault; F Gay-Andrieu; F Peyron
Journal:  Eur J Pediatr       Date:  1999-08       Impact factor: 3.183

2.  Performance of a Western blot assay to compare mother and newborn anti-Toxoplasma antibodies for the early neonatal diagnosis of congenital toxoplasmosis.

Authors:  F Robert-Gangneux; V Commerce; C Tourte-Schaefer; J Dupouy-Camet
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1999-09       Impact factor: 3.267

3.  Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling.

Authors:  D Dunn; M Wallon; F Peyron; E Petersen; C Peckham; R Gilbert
Journal:  Lancet       Date:  1999-05-29       Impact factor: 79.321

4.  Serological rebound in congenital toxoplasmosis: long-term follow-up of 133 children.

Authors:  M Wallon; G Cozon; R Ecochard; P Lewin; F Peyron
Journal:  Eur J Pediatr       Date:  2001-09       Impact factor: 3.183

5.  Classification system and case definitions of Toxoplasma gondii infection in immunocompetent pregnant women and their congenitally infected offspring. European Research Network on Congenital Toxoplasmosis.

Authors:  M Lebech; D H Joynson; H M Seitz; P Thulliez; R E Gilbert; G N Dutton; B Ovlisen; E Petersen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-10       Impact factor: 3.267

6.  Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children's sequelae at age 1 year.

Authors:  W Foulon; I Villena; B Stray-Pedersen; A Decoster; M Lappalainen; J M Pinon; P A Jenum; K Hedman; A Naessens
Journal:  Am J Obstet Gynecol       Date:  1999-02       Impact factor: 8.661

7.  Congenital toxoplasmosis: 10-year follow up.

Authors:  M Mombrò; C Perathoner; A Leone; M Nicocia; A Moiraghi Ruggenini; C Zotti; M A Lievre; C Fabris
Journal:  Eur J Pediatr       Date:  1995-08       Impact factor: 3.183

8.  Detection of Toxoplasma gondii in 94 placentae from infected women by polymerase chain reaction, in vivo, and in vitro cultures.

Authors:  H Fricker-Hidalgo; H Pelloux; C Racinet; I Grefenstette; C Bost-Bru; A Goullier-Fleuret; P Ambroise-Thomas
Journal:  Placenta       Date:  1998-09       Impact factor: 3.481

9.  Fetal toxoplasmosis: outcome of pregnancy and infant follow-up after in utero treatment.

Authors:  P Hohlfeld; F Daffos; P Thulliez; C Aufrant; J Couvreur; J MacAleese; D Descombey; F Forestier
Journal:  J Pediatr       Date:  1989-11       Impact factor: 4.406

  9 in total
  2 in total

1.  A meta analysis on risks of adverse pregnancy outcomes in Toxoplasma gondii infection.

Authors:  Xue-Lan Li; Hai-Xia Wei; Hao Zhang; Hong-Juan Peng; David S Lindsay
Journal:  PLoS One       Date:  2014-05-15       Impact factor: 3.240

2.  The impact of socioeconomic factors on the efficiency of voluntary toxoplasmosis screening during pregnancy: a population-based study.

Authors:  A E Lange; J R Thyrian; S Wetzka; S Flessa; W Hoffmann; M Zygmunt; C Fusch; H N Lode; M Heckmann
Journal:  BMC Pregnancy Childbirth       Date:  2016-07-29       Impact factor: 3.007

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.